Severity
Moderate
FDA Drug recall · Reported November 23, 2022
Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.
Viatris Inc recalled Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only, Mfg: Mylan Pharmaceuticals In… - a moderate-severity action.
Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only, Mfg: Mylan Pharmaceuticals In… was recalled by Viatris Inc in November 23, 2022. Reason: Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.. Check the official notice for the remedy. Verify recall #D-0063-2023 with the FDA Drug before acting.
The recall
Viatris Inc issued this moderate-severity FDA Drug recall-Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness..
Sourced from official FDA Drug enforcement records. Verify recall #D-0063-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0063-2023) was formally reported on November 23, 2022, with the manufacturer initiating the action on October 21, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. Viatris Inc is listed as the recalling firm, operating out of Canonsburg, PA. Federal records list the affected scope as 2,794 bottles.
The documented reason for this recall is: Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness. Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
2,794 bottles
Related Recalls
6
5 from same agency
Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only, Mfg: Mylan Pharmaceuticals Inc. Morgantown, WV 36505, Made in India, NDC 0378-3634-05
Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0063-2023 |
| Date reported | November 23, 2022 |
| Date initiated | October 21, 2022 |
| Recalling firm | Viatris Inc |
| Firm location | Canonsburg, PA |
| Affected scope | 2,794 bottles |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 23, 2022. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.